Table 8.

Literature verification of predicted direct compound-cardiovascular disease interactions

Predicted interactions	Validated literatures
Borneol (C8)—Hyperlipidemia (D16)	Borneol has ameliorative effect of hyperlipidemia in diabetic Wistar rats [32]
Cryptotanshinone (C10)—Diabetes mellitus type 2 (D20)	Cryptotanshinone has effect of antidiabetes via activation of AMP-activated protein kinase [33]
Ginsenoside-Rg1 (C18)—Diabetes mellitus type 2 (D20)	Ginsenoside-Rg1 can alleviate the insulin resistance through increasing the uptake of glucose and decreasing the output of glucose [34, 35]
Tanshinone IIA (C40)—Diabetes mellitus type 2 (D20)	Tanshinone IIA may alleviate type 2 DM symptoms in experimental rats [36]
Cryptotanshinone (C10)—Obesity (D12)	Cryptotanshinone promotes commitment to the brown adipocyte lineage and mitochondrial biogenesis in C3H10T1/2 mesenchymal stem cells to alleviate obesity [37]
Tanshinone IIA (C40)—Obesity (D12)	Tanshinone IIA may treat obesity through PPARγ [38]
Tanshinone IIA (C40)—Angina pectoris (D18)	Sodium tanshinone IIA silate can act as an add-on therapy in patients with unstable angina pectoris [39]
Ginsenoside-Rg1 (C18)—Acute Myocardial infarction (D1)	Ginsenoside-Rg1 could enhance angiogenesis and ameliorates ventricular remodeling in a rat model of Acute Myocardial infarction [40]